BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Doxycycline
,
rs2230926
,
DRD2
,
T cell receptor signaling pathway
,
Diabetes mellitus
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
natalizumab
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
ITGA4
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
clathrin-dependent extracellular exosome endocytosis
positive regulation of leukocyte tethering or rolling
positive regulation of leukocyte adhesion to vascular endothelial cell
protein antigen binding
VANLOO_SP3_TARGETS_UP
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
CD4+ T cells of seasonal allergic rhinitis and multiple sclerosis patients response to NZB or GC
CD4+ T cells stimulated and then restimulated in the presence or absence of natalizumab
Multiple sclerosis patients in remission and relapse
Drug target sets for approved compounds
Explore Curated Studies Results
Literature
Most Relevant Literature
PB006: A Natalizumab Biosimilar.
Intact natalizumab pharmacokinetics is impacted by endogenous IgG4 concentration.
Literature review and meta-analysis of natalizumab therapy for the treatment of highly active relaps…
Intravenous or subcutaneous natalizumab in patients with relapsing-remitting multiple sclerosis: inv…
Natalizumab for GVHD: too little or too late?
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Natalizumab Re-Initiation of Dosing
Natalizumab and Chronic Inflammation
Natalizumab Temporary Discontinuation Study
Open-Label Natalizumab Safety Extension Study
Natalizumab Subcutaneous Immunogenicity and Safety Study
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ